Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Sanchez

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Journal of the American Academy of Child and Adolescent Psychiatry|August 26, 2017
Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal StudyChristoph U Correll, Eva Kohegyi, Cathy Zhao, et al.
Journal of Child and Adolescent Psychopharmacology|July 8, 2017
Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and AdolescentsFloyd Sallee, Eva Kohegyi, Joan Zhao, et al.
International Clinical Psychopharmacology|April 26, 2013
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophreniaW Wolfgang Fleischhacker, Raymond Sanchez, Brian Johnson, et al.
NPJ Schizophrenia|June 24, 2016
Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label studyTimothy Peters-Strickland, Ross A Baker, Robert D McQuade, et al.
Journal of Psychopharmacology (Oxford, England)|January 13, 2006
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyGary Sachs, Raymond Sanchez, Ronald Marcus, et al.
Current Medical Research and Opinion|July 5, 2013
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazoleSteven G Potkin, Arash Raoufinia, Suresh Mallikaarjun, et al.
The International Journal of Neuropsychopharmacology|August 28, 2016
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled StudyW Wolfgang Fleischhacker, Mary Hobart, John Ouyang, et al.
Schizophrenia Research|February 16, 2015
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaJohn M Kane, Aleksandar Skuban, John Ouyang, et al.
The Journal of Clinical Psychiatry|May 4, 2006
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorderPaul E Keck, Joseph R Calabrese, Robert D McQuade, et al.
The American Journal of Psychiatry|April 18, 2015
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled TrialChristoph U Correll, Aleksandar Skuban, John Ouyang, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Child and Adolescent Psychiatry|August 26, 2017
Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal StudyChristoph U Correll, Eva Kohegyi, Cathy Zhao, et al.
Journal of Child and Adolescent Psychopharmacology|July 8, 2017
Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and AdolescentsFloyd Sallee, Eva Kohegyi, Joan Zhao, et al.
International Clinical Psychopharmacology|April 26, 2013
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophreniaW Wolfgang Fleischhacker, Raymond Sanchez, Brian Johnson, et al.
NPJ Schizophrenia|June 24, 2016
Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label studyTimothy Peters-Strickland, Ross A Baker, Robert D McQuade, et al.
Journal of Psychopharmacology (Oxford, England)|January 13, 2006
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyGary Sachs, Raymond Sanchez, Ronald Marcus, et al.
Current Medical Research and Opinion|July 5, 2013
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazoleSteven G Potkin, Arash Raoufinia, Suresh Mallikaarjun, et al.
The International Journal of Neuropsychopharmacology|August 28, 2016
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled StudyW Wolfgang Fleischhacker, Mary Hobart, John Ouyang, et al.
Schizophrenia Research|February 16, 2015
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaJohn M Kane, Aleksandar Skuban, John Ouyang, et al.
The Journal of Clinical Psychiatry|May 4, 2006
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorderPaul E Keck, Joseph R Calabrese, Robert D McQuade, et al.
The American Journal of Psychiatry|April 18, 2015
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled TrialChristoph U Correll, Aleksandar Skuban, John Ouyang, et al.
Pageof 6